huMNC2-CAR44

N/A

Report date: 2024/11/04 15:26:15

Base Information

Drug NamehuMNC2-CAR44
Drug Alias NamehuMNC2-scFv-CAR T cellsMUC1*-targeting CAR T cellshuMNC2-CAR44
ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapy
Mechanisms of ActionAnti-MUC1
TargetsMucin-1
Therapy Area/IndicationsMetastatic breast cancer
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaN/A
Originator CompaniesMinerva Biotechnologies Co
China Registration ClassN/A

Develop Information

Active CompaniesMinerva Biotechnologies Co
Inactive CompaniesN/A
Active IndicationsMetastatic breast cancer
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A